Stage IVA Thymoma Clinical Trial
Official title:
Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)
This phase II trial is studying how well saracatinib works in treating patients with relapsed or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
PRIMARY OBJECTIVES:
I. To evaluate the objective response rate (complete response and partial response) in
patients with relapsed or refractory thymoma or thymic carcinoma treated with AZD0530.
SECONDARY OBJECTIVES:
I. To evaluate the toxicity of AZD0530 in these patients. II. To evaluate the
progression-free survival of these patients. III. To evaluate the overall survival of these
patients. IV. To evaluate the disease control rate, defined as complete response, partial
response, and stable disease, in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in
the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 5 years.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04371458 -
Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies
|
Phase 1/Phase 2 |